ライフサイエンスコーパス: thyroid nodule

1 ken in all preadolescents (<13 years) with a thyroid nodule.

2 test for evaluating possible malignancy in a thyroid nodule.

3 75 [79%] female) who underwent surgery for a thyroid nodule.

4 ntify the probability of malignancy for each thyroid nodule.

5 .5 years) with a benign solitary or dominant thyroid nodule.

6 ncompass all newly evaluated patients with a thyroid nodule.

7 ull-length hTERT were associated with benign thyroid nodules.

8 for planning initial clinical management of thyroid nodules.

9 r preoperative guidance in the management of thyroid nodules.

10 cal tool for the evaluation of patients with thyroid nodules.

11 cation, size, number, and characteristics of thyroid nodules.

12 ism or the development of actively secreting thyroid nodules.

13 uld serve as diagnostic markers of malignant thyroid nodules.

14 mits the discrimination of specific types of thyroid nodules.

15 diagnostic tool in the initial evaluation of thyroid nodules.

16 munostaining techniques in the evaluation of thyroid nodules.

17 he pathogenesis, diagnosis, and treatment of thyroid nodules.

18 We evaluated a total of 127 thyroid nodules.

19 eatment of hypothyroidism, and management of thyroid nodules.

20 detected in any of the patients with benign thyroid nodules.

21 e detected in two patients (10%) with benign thyroid nodules.

22 capable of detecting many small, nonpalpable thyroid nodules.

23 rs associated with the development of benign thyroid nodules.

24 onsecutive patients underwent RFA for benign thyroid nodules.

25 ) over conventional US-guided FNAC alone for thyroid nodules.

26 al US FNAC in the diagnosis of malignancy in thyroid nodules.

27 ion malignancy diagnosis among patients with thyroid nodules.

28 es in the diagnostic management of pediatric thyroid nodules.

29 (US) is the method of choice for evaluating thyroid nodules.

30 at a younger age in patients with XP, as do thyroid nodules.

31 g in patients affected by thyrotoxicosis and thyroid nodules.

32 n patients presenting with Bethesda V and VI thyroid nodules.

33 ded FNAC in reducing nondiagnostic rates for thyroid nodules.

34 66.5%, respectively, in predicting malignant thyroid nodules.

35 hy can be a potential indicator of malignant thyroid nodules.

36 nostic accuracy of the GC test for pediatric thyroid nodules.

37 ly used in malignancy risk stratification of thyroid nodules.

38 HDMI images, improving the classification of thyroid nodules.

39 adolescence with the incidence of malignant thyroid nodules.

40 he remaining FNA tissue in the management of thyroid nodules.

41 s the primary diagnostic tool for evaluating thyroid nodules.

42 nd study for the identification of malignant thyroid nodules.

43 oid disorders, including Graves' disease and thyroid nodules.

44 reliably differentiate malignant and benign thyroid nodules.

45 for identification of malignant potential of thyroid nodules.

46 , neck palpation was not sensitive to detect thyroid nodules.

47 mas, but not in normal thyrocytes and benign thyroid nodules.

48 ecommendations for follow-up of asymptomatic thyroid nodules.

49 hyperthyroidism in adults without goiter or thyroid nodules.

50 safe procedure for treatment of benign solid thyroid nodules.

51 ancy risk assessment of follicular-patterned thyroid nodules.

52 tic, sonographically or cytologically benign thyroid nodules.

53 idelines were used for work-up of incidental thyroid nodules.

54 inct definitive management for patients with thyroid nodules.

55 ostic testing in cytologically indeterminate thyroid nodules.

56 ing examples that have improved diagnosis of thyroid nodules.

57 ome mandatory while evaluating patients with thyroid nodules.

58 NAC) is the standard diagnostic modality for thyroid nodules.

59 atients, and 4812 fine-needle aspirates from thyroid nodules 1 cm or larger that required evaluation.

60 is retrospective study, 192 biopsy-confirmed thyroid nodules (175 benign, 17 malignant) in 167 unique

61 126 [26.8%] were male) diagnosed with single thyroid nodules, 2117 (18.2%) received a biopsy.

62 tients with 20-mm or smaller Bethesda 5 to 6 thyroid nodules, 222 (86.3%) enrolled and selected treat

63 g adds diagnostic value to the evaluation of thyroid nodules 4-cm or larger is unknown.

64 f 288], P < .001) and multinodular goiter or thyroid nodule (40.7% [50 of 123] vs 29.2% [84 of 288],

65 my) or focal (i.e., autonomously functioning thyroid nodules [AFTN]) overactivity.

66 on biopsy in the evaluation of patients with thyroid nodule and predicting disease aggressiveness.

67 al of 229 patients had at least 1 documented thyroid nodule and were included in the analysis.

68 Of 192 screened FAP patients, 72 (38%) had thyroid nodules and 5 (2.6%) had thyroid cancer.

69 gland disorders include benign and malignant thyroid nodules and diffuse thyroid disorders.

70 elp in differentiating benign from malignant thyroid nodules and inform clinical decision making.

71 regarding overdiagnosis and overtreatment of thyroid nodules and low-risk papillary thyroid cancer.

72 re excellent diagnostic markers of malignant thyroid nodules and may be used to improve the diagnosti

73 on to the diagnostic workup of children with thyroid nodules and may decrease the use of diagnostic s

74 r imaging may aid exclusion of malignancy in thyroid nodules and molecular markers have great promise

75 ality control for radiofrequency ablation of thyroid nodules and parathyroid adenomas to optimize the

76 fe, and effective method for treating benign thyroid nodules and recurring thyroid cancer as well as

77 The authors examined risk factors for benign thyroid nodules and their influence on radiation effects

78 e simple differentiation of solid and cystic thyroid nodules and their measurement.

79 el molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting

80 The evaluation and management of thyroid nodules and thyroid cancer in pregnancy pose a p

81 patient-oriented and tailored management of thyroid nodules and thyroid cancer.

82 mary search terms molecular, thyroid cancer, thyroid nodule, and gene expression classifier in search

83 ing to malignancy, such as melanocytic nevi, thyroid nodules, and colonic polyps.

84 in irradiated glands, the natural history of thyroid nodules, and the prevalence of occult cancer wer

85 reatment of hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer in children and adol

86 ence of one or more autonomously functioning thyroid nodules, and thyroiditis caused by inflammation,

87 renal cysts, liver hemangiomas, liver cysts, thyroid nodules, and uterine leiomyomas.

88 of malignancy in cytologically indeterminate thyroid nodules; and peripheral blood and fine-needle as

89 Thyroid nodules are a common finding, especially in iodi

90 Although most thyroid nodules are benign, 10% to 15% of them harbor ca

91 Although most thyroid nodules are benign, the potential for malignant

92 Thyroid nodules are common and most often benign.

93 Although thyroid nodules are common, few are malignant and requir

94 all cancers are present in the thyroid, yet thyroid nodules are found in 4 to 10% of the adult popul

95 Thyroid nodules are found in 4 to 7% of the population,

96 ded fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate.

97 Only five percent of thyroid nodules are malignant.

98 Thyroid nodules are neoplasms commonly found among adult

99 Background Risk stratification systems for thyroid nodules are often complicated and affected by lo

100 Thyroid scintigraphy is recommended if thyroid nodules are present or the etiology is unclear.

101 Because thyroid nodules are relatively common, the diagnostic di

102 Thyroid nodules are uncommon but malignant in as many as

103 toms of hypothyroidism, hyperthyroidism, and thyroid nodules, as well as the general approach to eval

104 As thyroid nodules become more prevalent clinicians are inc

105 patients with a preoperative highly suspect thyroid nodule (Bethesda 5) or proven mPTC (Bethesda 6).

106 including 468 females (85.2%), operated for thyroid nodule between January 2005 and January 2019.

107 sed pediatric patients diagnosed with single thyroid nodules between 2003 and 2020.

108 r genetic alterations in diverse subtypes of thyroid nodules beyond PTC, including a variety of sampl

109 specificity of a deep learning algorithm for thyroid nodule biopsy recommendations was similar to tha

110 functioning nodules and one with functioning thyroid nodules, both of whom underwent radiofrequency a

111 for follicular carcinoma in Bethesda type IV thyroid nodules but their absence do not allow to predic

112 for follicular carcinoma in Bethesda type IV thyroid nodules but their absence does not allow to pred

113 to discriminate between malignant and benign thyroid nodules, but nondiagnostic results remain a clin

114 molecular testing improves the management of thyroid nodules, but this has not been validated in chil

115 facilitate a definitive cancer diagnosis of thyroid nodules by differentiating the variation extent

116 The evaluation of thyroid nodules by fine-needle aspiration has been the s

117 differentiating between benign and malignant thyroid nodules by offering a risk stratification model.

118 Ablation, Papillary Thyroid Microcarcinoma, Thyroid Nodules (C) RSNA, 2025.

119 s improved documentation of ultrasonographic thyroid nodule characteristics, potentially allowing for

120 r-frame correlation values and performed the thyroid nodule classification for the high motion contai

121 markers and evaluated their effectiveness in thyroid nodule classification.

122 of the patients (109 of 173) referred to the thyroid nodule clinic after abnormal results on thyroid

123 nts with concomitant suspicious or malignant thyroid nodules, coexisting hyperparathyroidism, and in

124 e molecular landscape of malignant pediatric thyroid nodules (compared with adults), which is dominat

125 ndings were discussed at a multidisciplinary thyroid nodule conference, and the decision was made to

126 ndings were discussed at a multidisciplinary thyroid nodule conference, and the decision was made to

127 pathologic and histopathologic evaluation of thyroid nodules, confirming an inherent limitation of vi

128 appropriate TUS, iTUS led to lower rates of thyroid nodule detection (202 of 866 [23.3%] vs 6885 of

129 Patients with toxic nodules (ie, in which thyroid nodules develop autonomous function) may have sy

130 on model was used to assess the time between thyroid nodule diagnosis and biopsy.

131 cancer type, age at diagnosis, sex, and past thyroid nodule diagnosis.

132 After exclusion of nonavid thyroid nodules, diffuse (18)F-FDG uptake, known thyroid

133 Approximately 20% of thyroid nodules display indeterminate cytology.

134 it can be helpful in the routine analysis of thyroid nodules, especially in clinical settings with mo

135 Approximately 15 to 30% of thyroid nodules evaluated by means of fine-needle aspira

136 eedle biopsy (FNB) became a critical part of thyroid nodule evaluation in the 1970s.

137 erapy does not seem to prevent recurrence of thyroid nodules except in patients with a history of rad

138 Mutation analysis in thyroid nodule fine needle aspiration biopsy has been ap

139 ith thyroid cancer, and molecular testing of thyroid nodule fine-needle aspiration (FNA) specimens ha

140 cally resected thyroid tumor tissues and 249 thyroid nodule FNA biopsies were obtained from 620 patie

141 Yet, up to 20% of thyroid nodule FNA biopsies will be indeterminate in dia

142 8 surgically resected thyroid tumors and 217 thyroid nodule FNA biopsy specimens, were collected from

143 Thyroid nodules frequently require ultrasound and Fine N

144 shouts of fine-needle aspiration biopsies of thyroid nodule from different patients.

145 ls and Methods A total of 1425 biopsy-proven thyroid nodules from 1264 consecutive patients (1026 wom

146 alignancy index in differentiating malignant thyroid nodules from benign ones.

147 Most solid, benign thyroid nodules grow.

148 Fine-needle aspiration biopsy of large thyroid nodules has a high false-negative rate and shoul

149 Percutaneous ablation of benign thyroid nodules has become a widely accepted alternative

150 Fine-needle aspiration (FNA) of thyroid nodules has become the primary diagnostic tool i

151 tine calcitonin measurement in patients with thyroid nodules has been advocated for early detection o

152 Detection of asymptomatic thyroid nodules has increased.

153 the patients presenting with a single benign thyroid nodule have contralateral subclinical disease.

154 Patients whose thyroid nodules have indeterminate or suspicious cytolog

155 The natural history of benign thyroid nodules, however, is unclear.

156 perthyroidism (HR, 1.8; 95% CI, 1.2 to 2.8), thyroid nodules (HR, 6.3; 95% CI, 5.2 to 7.5), thyroid c

157 Hyperfunctioning thyroid nodules (HTNs) were presumed to exclude malignan

158 g 229 patients who had at least 1 documented thyroid nodule identified on bedside clinic ultrasonogra

159 ess the malignant neoplasm risk potential of thyroid nodules imaged by ultrasonography.

160 Definitive diagnosis of a thyroid nodule in a child is obtained through diagnostic

161 ised 68 consecutive patients with a solitary thyroid nodule in whom fine-needle aspiration showed a f

162 clinical practice.ResultsIncluded were 1377 thyroid nodules in 1230 patients with complete imaging d

163 Seventy-one thyroid nodules in 71 consecutive patients were evaluate

164 RADS) is a recognized tool for management of thyroid nodules in adults but has not been validated in

165 This review of thyroid nodules in children indicates that the incidence

166 s In this retrospective study, a database of thyroid nodules in patients younger than 19 years who un

167 a for guiding decisions on whether to biopsy thyroid nodules in pediatric patients in a single referr

168 invasive, and practical method for assessing thyroid nodules in routine practice.

169 The high prevalence of thyroid nodules in the adult population and the relative

170 may significantly enhance the evaluation of thyroid nodules in the future.

171 and is part of the differential diagnosis of thyroid nodules in the pediatric population.

172 marker testing techniques for indeterminate thyroid nodules include gene expression classifier analy

173 used as an additional tool in the work-up of thyroid nodules instead of a single predictor of which l

174 Fine needle aspiration (FNA) biopsy of thyroid nodules is a safe, cost-effective, and accurate

175 nes whether body mass index in children with thyroid nodules is associated with thyroid cancer and a

176 Management of thyroid nodules is based on statistical data correlating

177 Preoperative characterization of thyroid nodules is challenging since thyroid scintigraph

178 Core-needle biopsy of thyroid nodules is effective because it diagnoses more t

179 System criteria for management of pediatric thyroid nodules is inadequate because a high percentage

180 The incidence of malignant thyroid nodules is low and the prognosis is good.

181 rease in size with complete disappearance of thyroid nodules is not uncommon.

182 The gold standard evaluation for thyroid nodules is ultrasound-guided fine-needle aspirat

183 To discuss the problem of incidental thyroid nodules (ITN) detected on imaging; summarize the

184 clinicians in the treatment of indeterminate thyroid nodules (ITNs).

185 esting impacted the finding of malignancy in thyroid nodules <4-cm.

186 osed a machine learning framework to predict thyroid nodule malignancy based on our collected novel c

187 Current human assessment of thyroid nodule malignancy is prone to errors and may not

188 framework over human judgment in predicting thyroid nodule malignancy.

189 ture guidelines and policies associated with thyroid nodule management.

190 BackgroundManagement of thyroid nodules may be inconsistent between different ob

191 Disparities in the workup of thyroid nodules may be significantly associated with thy

192 borders and microcalcifications) within such thyroid nodules may have a stronger correlation for thyr

193 Changes in the diagnostic approach to thyroid nodules may have resulted in an increase in the

194 ts younger than 5 years or the presence of a thyroid nodule, may make surgery the optimal treatment f

195 Thyroid nodule MT optimizes patient outcomes sufficientl

196 id lobes with healthy tissue (n = 8), benign thyroid nodules (n = 13), and malignant thyroid nodules

197 nign thyroid nodules (n = 13), and malignant thyroid nodules (n = 3).

198 Thyroid nodules (n = 5349) that underwent US-guided FNA

199 The molecular work-up of thyroid nodules on fine needle aspiration (FNA) cytology

200 rained to provide biopsy recommendations for thyroid nodules on the basis of two orthogonal US images

201 images showed alternative findings such as a thyroid nodule or metallic artifact.

202 ns for overt hyperthyroidism from autonomous thyroid nodules or Graves disease include antithyroid dr

203 As such, the diagnosis of thyroid nodules or thyroid cancer during pregnancy is be

204 idity and mortality, test accuracy to detect thyroid nodules or thyroid cancer, and harms resulting f

205 95% CI, 3.49-16.69), multinodular goiter or thyroid nodule (OR, 1.82; 95% CI, 1.01-3.28), and parath

206 eries examined all RFA procedures for benign thyroid nodules performed by 2 attending physicians at a

207 enetic markers help raise the suspicion of a thyroid nodule possibly harboring an aggressive cancer;

208 improve radiology workflow for management of thyroid nodules.PurposeTo develop a deep learning algori

209 these advancements have affected the size of thyroid nodules reported on ultrasonography over time.

210 The size of thyroid nodules reported via ultrasonography over time.

211 uidelines and practice patterns have changed thyroid nodule reporting over time and can inform future

212 Changes to thyroid nodule risk stratification systems and guideline

213 Several international ultrasound-based thyroid nodule risk stratification systems have been dev

214 yroid RFA across the US, an understanding of thyroid nodule rupture (TNR) is crucial for recognition,

215 A total of 118 thyroid nodule samples (95 FFPE, 23 companion FNAs) yiel

216 t uses thyroid US images to decide whether a thyroid nodule should undergo a biopsy and to compare th

217 iveness with which the diagnostic studies of thyroid nodules should be pursued.

218 Thyroid nodules should generally be studied with thyroid

219 Presence of thyroid nodules should prompt measurement of circulating

220 Malignant thyroid nodules showed significantly lower saturation of

221 ematic review and meta-analysis suggest that thyroid nodule size reported on diagnostic ultrasonograp

222 uld be an important tool in the selection of thyroid nodules suspected of malignancy and requiring hi

223 e aspiration biopsy identifies the childhood thyroid nodules that are at greatest risk for cancer.

224 conservative approach for most patients with thyroid nodules that are cytologically indeterminate on

225 life, presenting as progressively enlarging thyroid nodules that often yield non-diagnostic results

226 The MOD of thyroid nodules that were surgically removed, by geograp

227 tic, sonographically or cytologically benign thyroid nodules, the majority of nodules exhibited no si

228 ulation medians among the different types of thyroid nodules; the R software environment was used for

229 Patients with previous thyroid nodule, thyroid cancer, thyroid surgery, or TUS

230 s following iTUS, including the detection of thyroid nodules, thyroid procedures, and thyroid cancer

231 Thyroid nodules (TN) are prevalent in the general popula

232 during 2015-2020 on patients diagnosed with thyroid nodule undergoing ultrasound-guided fine-needle

233 or transfer learning tasks on small datasets-thyroid nodules (US), breast masses (US), anterior cruci

234 Thyroid nodules usually are an incidental finding on a r

235 Thyroid nodule volume, US structure, and Doppler pattern

236 Past thyroid nodule was consistently the strongest risk facto

237 cluding type Ir pleuropulmonary blastoma and thyroid nodules), we used the Kaplan-Meier method and no

238 total cohort assessed for eligibility, 3140 thyroid nodules were assessed, and 427 (13.6%) nodules w

239 Altogether, more than 80% of the autonomous thyroid nodules were classified as TIRADS 4A or higher,

240 Thyroid nodules were classified using ACR TI-RADS and TI

241 In follow-up through 1991, benign thyroid nodules were diagnosed in 131 patients.

242 A total of 1857 thyroid nodules were finally included, of which 84 were

243 c findings, and other reports on nonpalpable thyroid nodules were included.

244 therapy for solitary and predominantly solid thyroid nodules were reviewed.

245 One hundred twenty-one thyroid nodules were sampled for biopsy in 109 patients.

246 In these 314 patients, 404 thyroid nodules were scored, of which 19.1% (77 of 404)

247 and immunohistochemistry in the diagnosis of thyroid nodules, which may lead to a more rational appro

248 ove the clinical management of patients with thyroid nodules while reducing unnecessary surgery and s

249 Eligible adults with single or multiple thyroid nodules who had not previously undergone FNAC we

250 For thyroid nodules whose cytology shows a follicular neopla

251 Thyroid nodules whose FNA is diagnosed as highly suspici

252 phy seems promising in identifying malignant thyroid nodules with acceptable accuracy, further studie

253 arkers, which may help to identify malignant thyroid nodules with greater specificity.

254 testing is commonly used in the diagnosis of thyroid nodules with indeterminate cytology.

255 ing in prognosticating oncologic outcomes in thyroid nodules with suspicious or malignant cytology is

256 an discriminate between benign and malignant thyroid nodules with the necessary sensitivity and speci

257 ith basal serum calcitonin for patients with thyroid nodules would cost $11,793 per life-year saved (